Abaxis Launches The VetScan(R) HM5 a State-of-the-Art 5-Part Differential Veterinary Hematology Analyzer

Tuesday, September 18, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

UNION CITY, Calif., Sept. 17 Abaxis, Inc.(Nasdaq: ABAX), a medical products company manufacturing point-of-care bloodanalysis systems for both the medical and veterinary markets, introduced todaythe VetScan HM5, a fully-automated 5-part differential cell counterspecifically designed for veterinary applications. The VetScan HM5 provides acomprehensive 22-parameter complete blood count with cellular histograms injust minutes for cat, dog and horse, and offers a 3-part mode for seven otherspecies.

The versatile VetScan HM5 incorporates superior performance, ease of use,offers true database management and minimal maintenance making it anattractive alternative for veterinary clinics, research laboratories, andpharmaceutical/biotech companies either using a commercial lab or in househematology instruments. Other advantages over competitive in house instrumentsinclude a 20% lower operating cost, a 50% smaller sample size and 40% fastertime to results.

"The VetScan HM5 provides veterinary practices the ability to arrive atmore timely diagnoses and treatment plans that can improve patient outcomesand quality of life," said Larry Lem, Abaxis Hematology Product Manager."With its well-documented accuracy, dependable reproducibility, ease of useand its significant cost savings as compared to the commercial lab, theVetScan HM5 will become an essential tool in improving the efficiency ofveterinary practices across the globe.

The new VetScan HM5 requires seconds of hands-on time to perform completeblood count (CBC) measurements on 10 available species. The operator entersthe appropriate patient information, inserts a well-mixed blood sample andpresses the "start" button. In just two minutes, test results and fourcellular histograms will be displayed, permitting the veterinarian to completea routine annual check-up, and/or make a timely diagnosis and devise anappropriate treatment plan.

Martin Mulroy, Vice President Marketing and Sales for the Veterinarybusiness added, "We have significantly ramped up both our field sales team andinside sales group in anticipation of this product release in order to bettermeet the expected demand. Abaxis now offers the marketplace a choice inhematology instruments, the VetScan HM2 and VetScan HM5, and is poised tocompete on multiple levels. This product line extension will also allow forincreased complete system placements, increasing demand and sales of theAbaxis VetScan VS2 chemistry, electrolytes and immunoassay system and theassociated rotors."

About Abaxis, Inc.

Abaxis develops, manufactures and markets portable blood analysis systemsfor use in any veterinary or human patient-care setting to provide clinicianswith rapid blood constituent measurements. The system consists of a compact,5.1 kilogram (11.2 pounds), portable analyzer and a series of single-useplastic discs, called reagent discs that contain all the chemicals required toperform a panel of up to 13 tests on veterinary patients and 14 tests on humanpatients. The system can be operated with minimal training and performsmultiple routine tests on whole blood, serum or plasma samples. The systemprovides test results in less than 12 minutes with the precision and accuracyequivalent to a clinical laboratory analyzer. The veterinary business alsoprovides to the veterinarian and research market now a line of hematologyinstruments for point of care complete blood counts (CBC).

This press release includes statements that constitute "forward-lookingstatements" within the meaning of the Private Securities Litigation Reform Actof 1995. Abaxis claims the protection of the safe-harbor for forward-lookingstatements contained in the Reform Act. Specific forward-looking statementscontained in this press release include, but are not limited to, risks anduncertainties related to the market acceptance of the Company's products andthe continuing

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store